ATE489455T1 - Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung - Google Patents

Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung

Info

Publication number
ATE489455T1
ATE489455T1 AT05804341T AT05804341T ATE489455T1 AT E489455 T1 ATE489455 T1 AT E489455T1 AT 05804341 T AT05804341 T AT 05804341T AT 05804341 T AT05804341 T AT 05804341T AT E489455 T1 ATE489455 T1 AT E489455T1
Authority
AT
Austria
Prior art keywords
dendritic cells
agonist
signaling
methods
receptor
Prior art date
Application number
AT05804341T
Other languages
English (en)
Inventor
Don Healey
Irina Tcherepanova
Melissa Adams
Atsushi Hinohara
Original Assignee
Argos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics Inc filed Critical Argos Therapeutics Inc
Application granted granted Critical
Publication of ATE489455T1 publication Critical patent/ATE489455T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05804341T 2004-10-07 2005-10-07 Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung ATE489455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52251204P 2004-10-07 2004-10-07
PCT/US2005/036304 WO2006042177A2 (en) 2004-10-07 2005-10-07 Mature dendritic cell compositions and methods for culturing same

Publications (1)

Publication Number Publication Date
ATE489455T1 true ATE489455T1 (de) 2010-12-15

Family

ID=36148973

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05804341T ATE489455T1 (de) 2004-10-07 2005-10-07 Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung

Country Status (13)

Country Link
US (4) US20080145931A1 (de)
EP (2) EP1809737B9 (de)
JP (2) JP5269412B2 (de)
KR (1) KR101243577B1 (de)
CN (1) CN101080487B (de)
AT (1) ATE489455T1 (de)
AU (1) AU2005294150B2 (de)
CA (1) CA2577125C (de)
DE (1) DE602005025005D1 (de)
DK (1) DK1809737T3 (de)
ES (1) ES2861199T3 (de)
TW (1) TWI382843B (de)
WO (1) WO2006042177A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
ATE489455T1 (de) * 2004-10-07 2010-12-15 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
CN101155914B (zh) 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US9249423B2 (en) * 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
DE102007006736B4 (de) 2007-02-07 2012-01-12 Dagmar Briechle In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz
US8802098B2 (en) 2007-04-25 2014-08-12 Immurx, Inc. Methods of promoting antitumor immunity by administering CD40 agonists and alpha-galactosyl ceramide
EP2201100B1 (de) * 2007-09-14 2016-03-16 Vrije Universiteit Brussel Verbesserung der t-zellen stimulierenden fähigkeit menschlicher antigenpräsentierender zellen und deren verwendung bei impfungen
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
US9408909B2 (en) 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
JP2011502165A (ja) * 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
EP2072617A1 (de) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Verfahren zur Herstellung dendritischer Zellen
WO2009145853A1 (en) * 2008-04-16 2009-12-03 Virostatics Srl Novel assay for precursor t-cells having high proliferative capacity (phpc-assay)
KR101527260B1 (ko) 2008-11-14 2015-06-08 디나벡크 가부시키가이샤 수상세포의 제조방법
EP2374813A1 (de) 2008-12-03 2011-10-12 Proyecto de Biomedicina Cima, S.L. Verwendung von phenollöslichen modulinen zur entwicklung von impfstoffen
KR20120093193A (ko) * 2009-09-04 2012-08-22 신젠타 파티서페이션즈 아게 식물 폴리펩티드 발현 증가를 위한 번역 향상제 요소의 적층
CA3095576A1 (en) * 2009-12-04 2011-06-09 Astellas Institute For Regenerative Medicine Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
CN104769104A (zh) * 2011-12-12 2015-07-08 细胞药物有限公司 扩大t细胞的方法
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
AU2014245806B2 (en) * 2013-03-28 2019-10-31 The University Of British Columbia Microfluidic devices and methods for use thereof in multicellular assays of secretion
JP2016081562A (ja) 2014-10-09 2016-05-16 ソニー株式会社 表示装置、表示装置の製造方法および電子機器
EP3268012A4 (de) 2015-03-12 2018-10-31 Health Research, Inc. Anreicherung von cd16+-monozyten zur verbesserung der dendritischen zellimpfstoffqualität
CN105670994A (zh) * 2016-02-28 2016-06-15 深圳爱生再生医学科技有限公司 Dc诱导剂及其应用
WO2017186121A1 (zh) * 2016-04-26 2017-11-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
CA3081616A1 (en) 2017-11-07 2019-05-16 Coimmune, Inc. Methods and uses for dendritic cell therapy
US20210277354A1 (en) * 2018-06-19 2021-09-09 Fondazione Telethon Production of engineered dendritic cells and uses thereof
EA202190267A1 (ru) 2018-07-15 2021-05-17 Инокиан Байофарма, Инк. Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
CN109797209B (zh) * 2019-01-04 2021-07-16 中国人民解放军第二军医大学 一种树突状细胞和/或趋化性树突状细胞和/或其趋化状态和功能的特异性生物标志物
US20220186224A1 (en) * 2019-04-11 2022-06-16 The Board Of Trustees Of The University Of Arkansas CD40 Specific DNA Aptamers as Vaccine Adjuvants
JP7612617B2 (ja) * 2019-06-17 2025-01-14 レノヴァロ バイオファーマ インコーポレイテッド 細胞性免疫及び体液性免疫を誘導するための同種異系ｔ細胞ベースのｈｉｖワクチン
AU2024356278A1 (en) * 2023-10-05 2026-02-26 Amgen Inc. Major histocompatibility complex (mhc)-associated peptide proteomics (mapps) assay for immunogenicity risk assessment of biotherapeutic attributes
WO2025147510A1 (en) * 2024-01-05 2025-07-10 Renovaro Biopharma Inc. Methods and compositions using recombinant dendritic cells for cancer therapy

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068910B2 (ja) 1990-11-08 2000-07-24 麒麟麦酒株式会社 新規スフィンゴ糖脂質、その製造法および使用
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
EP0563485A1 (de) 1992-03-30 1993-10-06 Schering-Plough In-vitro-Erzeugung von menschlichen dendritischen Zellen
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
TW261533B (de) 1992-07-16 1995-11-01 Kirin Brewery
EP0666268B1 (de) 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Neues sphingolglycolipid und verwendung davon
EP0694558B1 (de) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Sphingoglycolipid und verwendung davon
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
EP1637608B1 (de) 1993-10-25 2009-07-22 CANJI, Inc. Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
PL181496B1 (pl) 1996-03-20 2001-07-31 Politechnika Slaska Im Wincent Sposób wytwarzania ß-naftolu PL
NZ333607A (en) * 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
US6017527A (en) 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
TW555562B (en) 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
ATE286735T1 (de) 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
TW575420B (en) 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
JP5546084B2 (ja) 1998-05-26 2014-07-09 オプサニテクス エルエルシー 抗原に対する免疫応答を調節する組成物および方法
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1185627A2 (de) * 1999-06-01 2002-03-13 Cornell Research Foundation, Inc. Aktivierung von dendritischen zellen zur verstärkung der immunität
US6482411B1 (en) * 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
DK2336187T3 (en) 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
WO2001098317A2 (en) 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
AU2002232447A1 (en) 2000-11-02 2002-05-15 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
DE60108661T2 (de) 2000-11-14 2006-01-05 Université Libre de Bruxelles Herstellung und verwendung von dendritischen zellen
FR2819263B1 (fr) 2001-01-10 2003-04-11 Lco Sante Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740
AU2002240877B2 (en) 2001-01-15 2007-03-29 I.D.M. Immuno-Designed Molecules Ancillary composition for the preparation of committed mature dendritic cells
WO2002074345A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University School Of Medicine Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
EP1270732A1 (de) 2001-06-21 2003-01-02 Schuler, Gerold Transfektion von eukaryotischen Zellen mit linearen Polynukleotiden mittels Elektroporation
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
CA2454734A1 (en) * 2001-07-25 2003-02-06 I.D.M. Immuno-Designed Molecules New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
US20040072347A1 (en) 2001-07-27 2004-04-15 Gerold Schuler Generation of fully mature and stable dendritic cells from leukaphereses products for clinical applications
DE60215530T2 (de) 2001-08-16 2007-05-31 Daiichi Asubio Pharma Co., Ltd. Neues glykolipid, und heilmittel für autoimmunerkrankungen, das dieses als wirkstoff enthält
EP1444330A1 (de) * 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Vermehrung von t-zellen in vitro und vermehrte t-zell populationen
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004031276A2 (en) * 2002-09-19 2004-04-15 Centocor, Inc. Method of inducing maturation of dendritic cells and uses therefor
WO2004026318A1 (ja) * 2002-09-20 2004-04-01 Kirin Beer Kabushiki Kaisha α-グリコシルセラミドを有効成分とするＣ型肝炎ウイルス抑制剤
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
US20060239962A1 (en) 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US20050003533A1 (en) * 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
US7060111B2 (en) 2003-07-03 2006-06-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method for providing more vibrant, natural and long-lasting color to hair
CN1964626A (zh) * 2004-03-31 2007-05-16 纽约大学 新型合成c－糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
ATE489455T1 (de) 2004-10-07 2010-12-15 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung

Also Published As

Publication number Publication date
US9556455B2 (en) 2017-01-31
EP2251418A1 (de) 2010-11-17
DK1809737T3 (da) 2011-03-07
EP1809737A2 (de) 2007-07-25
KR20070101233A (ko) 2007-10-16
HK1105997A1 (en) 2008-02-29
EP1809737B1 (de) 2010-11-24
US20170096640A1 (en) 2017-04-06
US20060078994A1 (en) 2006-04-13
CA2577125C (en) 2016-01-12
CN101080487A (zh) 2007-11-28
EP1809737B9 (de) 2011-10-05
AU2005294150B2 (en) 2011-06-16
CN101080487B (zh) 2012-11-14
US11248209B2 (en) 2022-02-15
US20150072431A1 (en) 2015-03-12
JP2013121352A (ja) 2013-06-20
TWI382843B (zh) 2013-01-21
EP2251418B1 (de) 2021-03-17
US8822223B2 (en) 2014-09-02
DE602005025005D1 (de) 2011-01-05
JP2008515439A (ja) 2008-05-15
ES2861199T3 (es) 2021-10-06
CA2577125A1 (en) 2006-04-20
AU2005294150A1 (en) 2006-04-20
US20080145931A1 (en) 2008-06-19
WO2006042177A2 (en) 2006-04-20
TW200630491A (en) 2006-09-01
WO2006042177A3 (en) 2007-02-01
JP5269412B2 (ja) 2013-08-21
KR101243577B1 (ko) 2013-03-20

Similar Documents

Publication Publication Date Title
ATE489455T1 (de) Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
ATE510451T1 (de) Zusammensetzungen mit reifen dendritischen zellen und verfahren zu ihrer kultivierung
JP6788629B2 (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
JP2009533025A5 (de)
Ziegler Thymic stromal lymphopoietin and allergic disease
Baxevanis et al. Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice
ES2924709T3 (es) Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
JP2008515439A5 (de)
WO2001077171A3 (en) Soluble zalpha11 cytokine receptors
BRPI0212545A8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
Guo et al. Fractalkine transgene induces T‐cell‐dependent antitumor immunity through chemoattraction and activation of dendritic cells
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
TN2012000138A1 (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
IL163067A (en) Isolated heterodimeric cytokine receptor
IL187628A (en) Method of culturing human embryonic stem cells into dendritic cells
JP2005505270A5 (de)
Okada et al. Differentiation of germinal center B cells and follicular helper T cells as viewed by tracking Bcl6 expression dynamics
WO2017100338A4 (en) Improved compositions and methods for viral delivery of neoepitopes and uses thereof
Trepiakas et al. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function
RU2020109423A (ru) Способы и композиции для получения сурфактантного белка d (sp-d)
ATE315653T1 (de) Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
Eshel et al. Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing
UA91325C2 (ru) Полимерные конъюгаты цитокинов, хемокинов, факторов роста, полипептидных гормонов и их антагонистов с сохраненной активностью рецепторного связывания
CN103522432B (zh) 硅块切割方法及其切割装置
AU2003217758A1 (en) Cytokines and cytokine receptors with reduced immunogenicity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1809737

Country of ref document: EP